I11 Hypertensive heart disease
One study in Hypertensive heart disease is accessible to registered UDBN website users.
British Genetics of Hypertension (BRIGHT) study
Prof Mark Caulfield (London and St Bart's Hospital)
As we enter the new Millennium, technological advances such as the human genome mapping project and high throughput genotyping present a major opportunity to define the genetic factors underpinning common diseases, such as hypertension, which remain a major threat to public health. The MRC British Genetics of Hypertension (BRIGHT) Study is a national collaboration, which has phenotyped 1500 hypertensive families, based upon affected sibling pairs, with the primary goal of undertaking a genome wide screen. The combination of a stable, high-density population and a strong MRC General Practice framework with a high reputation in cardiovascular studies in the UK has enabled us to establish a large family collection in a highly competitive timescale. The MRC have awarded a supplement to enable recruitment and phenotyping of 1000 parent-offspring trios, which is the optimal family structure for family based association studies using the transmission disequilibrium test (TDT). This will enable fine mapping and confirmation of regions of linkage identified from our genome screen and will allow causative genetic variants or haplotypes to be resolved, offering substantial added value to the BRIGHT study. In order to protect the existing limited BRIGHT DNA resource, we now seek funding to establish immortalised cell lines from which a National DNA repository may be generated to provide a plentiful supply of DNA for studies on hypertension. In tandem with our extensive phenotypic data, held in a purpose written Microsoft Access BRIGHT database, we believe that the BRIGHT study families (hypertensive sib pairs and TDT trios) will provide UK cardiovascular research, with possibly the best resource in the World from which to map genes for hypertension and other common cardiovascular diseases. Furthermore, we will have strong platform for international (especially European) collaboration and major research training and most importantly, the chance to improve the health of our nation, with novel therapies and diagnosis.
To access individual data and samples, first register.
